Optimal frailty assessment tool for elderly patients with heart failure based on outcome prediction: protocol for a multicentre prospective cohort study.

Abstract

Frailty significantly influences the prognosis of elderly patients diagnosed with heart failure. The assessment of frailty is a critical initial step in the management of these patients, as a systematic and precise evaluation facilitates the identification of individuals at high risk. This identification enables timely and targeted interventions, which can subsequently reduce the likelihood of adverse cardiovascular events and improve the quality of life for elderly patients with heart failure. Nevertheless, there exists a notable deficiency in research regarding the most effective frailty assessment tools specifically for elderly patients with heart failure in China. The objective of this study is to identify the frailty assessment tool that demonstrates the highest predictive value for outcomes in this population. This study is a multicentre, prospective cohort investigation that commenced in October 2023 across three tertiary hospitals in Beijing, China. Employing a continuous enrolment strategy, the study encompasses all elderly patients diagnosed with heart failure who are undergoing either outpatient or inpatient treatment, continuing until an adequate sample size is achieved. Follow-up evaluations are scheduled every 3 months from the point of patient enrolment, extending until the 12th month post-enrolment. Comprehensive data collection, which includes demographic information, heart failure-related metrics, frailty assessments and significant biochemical test results, is conducted through face-to-face interviews at baseline. Participant inclusion will depend on obtaining written informed consent from the patient or guardian. The trial protocol was approved by the Central Ethics Committee of Beijing Hospital. The approval letter number is 2023BJYYEC-356-01. Outcomes of the study will be published in a peer-reviewed scientific journal.